Cargando…
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study
OBJECTIVE: This study aims to analyse the effect of the discontinuation of anti-calcitonin gene-related peptide antibodies on monthly migraine days after 12 treatment months. BACKGROUND: Anti-calcitonin gene-related peptide antibodies have been a game changer in migraine prophylaxis. However, high t...
Autores principales: | Gantenbein, Andreas R, Agosti, Reto, Gobbi, Claudio, Flügel, Dominique, Schankin, Christoph J, Viceic, Dragana, Zecca, Chiara, Pohl, Heiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504406/ https://www.ncbi.nlm.nih.gov/pubmed/34000847 http://dx.doi.org/10.1177/03331024211014616 |
Ejemplares similares
-
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
por: Gantenbein, Andreas R., et al.
Publicado: (2022) -
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
por: Gantenbein, Andreas R., et al.
Publicado: (2022) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023) -
CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009) -
CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)